我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
9
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
11.1%
已完成
5
55.6%
招募中
2
22.2%
撤回
暂无批准数据
- Cinclus Pharma has initiated the HEEALING 1 Phase III study to evaluate linaprazan glurate for treating erosive gastroesophageal reflux disease (GERD) following positive regulatory feedback. - The study will enroll approximately 500 patients across seven European countries to demonstrate superiority over existing proton pump inhibitors like lansoprazole. - Linaprazan glurate could become the first potassium-competitive acid blocker (PCAB) approved in Europe, representing a significant advancement in GERD treatment. - The company has secured a strategic partnership with Zentiva valued at EUR 220 million, with plans to extend development to the US market through a second Phase III study.
